Dr. Schoffski Discusses Findings from the CREATE Study

Video

Patrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses the findings from the CREATE study during the 2018 AACR Annual Meeting.

Patrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses findings from the EORTC 90101/CREATE study presented during the 2018 AACR Annual Meeting.

The phase II prospective precision medicine CREATE trial investigated crizotinib (Xalkori) in patients with advanced, inoperable inflammatory myofibroblastic tumors with or without ALK alterations. Among 12 eligible and evaluable ALK-positive patients, 6 achieved a confirmed partial or complete response, 1 a non-confirmed partial response. Five patients had stable disease as best response.

In the ALK-positive population, there was an overall response rate of 50%, with a disease control rate of 100%. In those with ALK-negative disease, there were sporadic responses and disease stabilization, notes Schöffski. Common crizotinib-related adverse events were nausea (55%), fatigue (45%), blurred vision (45%), vomiting (35%), diarrhea (35%).

<<< 2018 AACR Annual Meeting

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center